International Stem Cell Corporation Receives Key Stem Cell Patent in Australia
October 31 2017 - 9:00AM
InvestorsHub NewsWire
CARLSBAD, CA -- October 31, 2017 -- InvestorsHub NewsWire
-- International Stem Cell Corporation (OTCQB:
ISCO) (www.internationalstemcell.com)
("ISCO" or "the Company"), a California-based clinical stage
biotechnology company that develops novel stem cell-based therapies
and biomedical products, announced today that ISCO's patent
covering methods for generating HLA homozygous parthenogenetic
human stem cell lines from unfertilized eggs has been issued in
Australia. This new development significantly strengths ISCO's
intellectual property position and partnering ability in the
Asia-Pacific region.
"With its unique potential to match patients’ immune system and to
avoid the ethical concerns surrounding the use of human embryonic
stem cells for treatment of injuries and diseases, our proprietary
stem cell platform is a break-through in the field of regenerative
medicine” commented Russell Kern, PhD., Executive Vice President
and Chief Scientific Officer of ISCO. “A comprehensive intellectual
property portfolio is essential for investors and potential
partners, as we are conducting our Parkinson’s disease clinical
study using ISC-hpNSC derived from pluripotent stem cells using the
technology described in this new patent. Additionally, ISCO has a
built-in competitive advantage since it is now possible to patent
human parthenogenetic stem cells in the European Union while IP
protection for embryonic stem cells remains restricted,” he
continued.
About International Stem Cell Corporation
International Stem Cell Corporation (ISCO)
is focused on the therapeutic applications of human parthenogenetic
stem cells (hpSCs) and the development and commercialization of
cell-based research and cosmetic products. ISCO's core technology,
parthenogenesis, results in the creation of human pluripotent stem
cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues
associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenetic, homozygous
stem cell line that can be a source of therapeutic cells for
millions of individuals of differing genders, ages, and racial
background with minimal immune rejection after transplantation.
hpSCs offer the potential to create the first true stem cell bank,
UniStemCell™. ISCO also produces and markets specialized cells and
growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology (www.lifelinecelltech.com),
and stem cell-based skin care products through its subsidiary
Lifeline Skin Care (www.lifelineskincare.com).
More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please
click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company
updates and industry related news, visit:
www.facebook.com/InternationalStemCellCorporation and
www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments, expected results
and timing of clinical studies, progress of research and
development initiatives, potential applications for ISC-hpNSC® and
other opportunities for the company and its subsidiaries, along
with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as "will," "believes," "plans," "anticipates," "expects,"
"estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products,
regulatory approvals, need and ability to obtain future capital,
application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the company's business,
particularly those mentioned in the cautionary statements found in
the company's Securities and Exchange Commission filings. The
company disclaims any intent or obligation to update
forward-looking statements.
International Stem Cell Corporation
Dr. Russell Kern
EVP, Chief Scientific Officer
(760)940-6383
ir@intlstemcell.com
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Apr 2023 to Apr 2024